title: Rotavirus vaccines: a story of success.
abstract: By January 2015, rotavirus vaccination had been implemented in national vaccination programmes in 75 countries worldwide. Two live oral rotavirus vaccines are internationally available: human, monovalent vaccine and human-bovine pentavalent reassortant vaccine. Since January 2014, another live, oral human-bovine monovalent vaccine has been available in India. After implementation of rotavirus vaccines in childhood immunization programmes, there has been an over 90% reduction of rotavirus hospitalizations in industrialized and resource-deprived countries. Additionally, in Latin America, significant reduction of rotavirus-associated deaths has been recorded. Still, numerous countries do not recommend rotavirus mass vaccination because of assumed lack of cost-effectiveness and potential risk of intussusception, which is estimated at 1 per 50 000-70 000 doses of rotavirus vaccines. Cost-effectiveness of vaccination is affected in some countries by high price. Inclusion of herd protection and indirect costs in calculations for cost-effectiveness results in clear benefit: costs saved by health systems due to reduced rotavirus gastroenteritis hospitalizations far exceed the costs for implementation of rotavirus vaccination. There have been objections that high rotavirus vaccination coverage could put selective pressure on certain rotavirus strains against which protection after vaccination is less distinct. However, data now strongly suggest that even if there might be a relative increase of some specific genotypes after the use of rotavirus vaccines, this is not an absolute increase in incidence from certain genotypes and does not affect the overall effectiveness of rotavirus mass vaccination, which resulted in a major decrease of severe cases of rotavirus gastroenteritis in both industrialized and resource deprived countries.
authors: Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria.
authors: H
authors: H
authors: Kollaritsch
authors: Institute of Environmental Health, Centre for Public Health, Medical University Vienna, Vienna, Austria.
authors: M
authors: M
authors: Kundi
authors: Department of Women and Child Health, University of Padova, Padova, Italy.
authors: C
authors: C
authors: Giaquinto
authors: Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Austria. Electronic address: maria.paulke-korinek@meduniwien.ac.at.
authors: M
authors: M
authors: Paulke-Korinek
mesh_terms: D003362:Cost-Benefit Analysis; D014943:Global Health; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D007443:Intussusception / Q000139:chemically induced / Q000453:epidemiology; D012400:Rotavirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*
chemical_list: D022243:Rotavirus Vaccines
keywords: Circulating genotypes; cost effectiveness; field effectiveness; intussusception; rotavirus vaccination